EDSA News and Press, Edesa Biotech Inc. From 02/02/21

TORONTO, ON / ACCESSWIRE / February 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of it...

Gainers: Express (EXPR) +278%.Koss (KOSS) +242%.AMC Entertainment (AMC) +184%.GameStop (GME) +124%.Fossil Group (FOSL) +121%.CEL-SCI (CVM) +83%.Naked Brand (NAKD) +80%.Nokia (NOK) +42%.Transocean (RIG) +38%.Vir Biotechnology (VIR) +34%.Losers: 1847 Goedeker (GOED) -21...

Gainers: Vir Biotechnology VIR +61%, Regional Health Properties (RHE) +26%, PetMed Express PETS +26%, SOS (SOS) +26%, Accelerate Diagnostics (AXDX) +25%.Losers: Edesa Biotech (EDSA) -15%, T2 Biosystems (TTOO) -12%, Celsion CLSN -12%,...

Looking For The Best Biotech Stocks For Your Watchlist? 3 Names To Know While many investors would agree that 2020 was the year for biotech stocks to shine, we may be able to say the same for 2021. The industry continues to bring huge gains for investors. Evidently, we see this ...

T2 Biosystems (TTOO) -20% despite strong Q4 & FY20 prelims.AIkido Pharma (AIKI) -18%.Seanergy Maritime Holdings (SHIP) -18%.Celsion CLSN -15%.Recon Technology (RCON) -15%.TransEnterix (TRXC) -14% after $69.25M capital raise.Ocugen (OCGN) -14%.BIOLASE (BIOL) -15%.P...

Gainers: Oxbridge Re (OXBR) +62%.Koss (KOSS) +60%.AIkido Pharma (AIKI) +51%.Vertex Energy (VTNR) +56%.Phunware (PHUN) +45%.Edesa Biotech (EDSA) +33%.CarParts.com (PRTS) +32%.Workhorse Group (WKHS) +30%.Orbital Energy (OEG) +27%.Vir Biotechnology (VIR) +27%.Losers: Express ...

Edesa Biotech (EDSA) +97% on regulatory nod for sub set of phase2/3 EB05 COVID-19 study.Koss Corporation (KOSS) +84%.Phunware (PHUN) +65%.Vertex Energy (VTNR) +52%.Myomo (MYO) +33% on JV to manufacture and sell the company’s products in China.AIkido Pharma (AIKI) +2...

Clinical-stage biopharma Edesa Biotech (EDSA) gets regulatory approval from the U.S. FDA and Health Canada to add a sub-study to its ongoing Phase 2/3 study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome ((ARDS)) - the leading cause of death i...

TORONTO, ON / ACCESSWIRE / January 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of...

Par Nijhawan, CEO of Edesa Biotech ([[EDSA]] +15.5%) is scheduled to join a panel discussion on COVID-19 organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate.In the ...